Literature DB >> 17538154

Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.

Ida Iurisci, Tyvin Rich, Francis Lévi, Pasquale F Innominato, Nicola Tinari, Luciana Irtelli, Michele De Tursi, Antonino Grassadonia, Stefano Iacobelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17538154     DOI： 10.1200/JCO.2007.11.3274

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Rest/activity rhythm is related to the coexistence of pain and sleep disturbance among advanced cancer patients with pain.

Authors:  Chen-Lai Ma; Wen-Pei Chang; Chia-Chin Lin
Journal:  Support Care Cancer       Date:  2013-09-01       Impact factor: 3.603

Review 2.  Systems Chronotherapeutics.

Authors:  Annabelle Ballesta; Pasquale F Innominato; Robert Dallmann; David A Rand; Francis A Lévi
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

3.  The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancer.

Authors:  James F Grutsch; Carol Ferrans; Patricia A Wood; Jovelyn Du-Quiton; Dinah Faith T Quiton; Justin L Reynolds; Christine M Ansell; Eun Young Oh; Mary Ann Daehler; Robert D Levin; Donald P Braun; Digant Gupta; Christopher G Lis; William J M Hrushesky
Journal:  BMC Cancer       Date:  2011-05-23       Impact factor: 4.430

4.  Validation of actigraphy to assess circadian organization and sleep quality in patients with advanced lung cancer.

Authors:  James F Grutsch; Patricia A Wood; Jovelyn Du-Quiton; Justin L Reynolds; Christopher G Lis; Robert D Levin; Mary Ann Daehler; Digant Gupta; Dinah Faith T Quiton; William Jm Hrushesky
Journal:  J Circadian Rhythms       Date:  2011-05-18

5.  Association of fatigue and depression with circulating levels of proinflammatory cytokines and epidermal growth factor receptor ligands: a correlative study of a placebo-controlled fatigue trial.

Authors:  Tyvin Rich; Fengmin Zhao; Ricardo A Cruciani; David Cella; Judith Manola; Michael J Fisch
Journal:  Cancer Manag Res       Date:  2017-01-31       Impact factor: 3.989

6.  Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer.

Authors:  Oxana Palesh; Luke Peppone; Pasquale F Innominato; Michelle Janelsins; Monica Jeong; Lisa Sprod; Josee Savard; Max Rotatori; Shelli Kesler; Melinda Telli; Karen Mustian
Journal:  Nat Sci Sleep       Date:  2012-12-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.